Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PGNX

Progenics Pharmaceuticals (PGNX) Stock Price, News & Analysis

Progenics Pharmaceuticals logo

About Progenics Pharmaceuticals Stock (NASDAQ:PGNX)

Advanced Chart

Key Stats

Today's Range
$3.94
$4.79
50-Day Range
$4.10
$4.10
52-Week Range
$1.89
$6.37
Volume
34.93 million shs
Average Volume
1.16 million shs
Market Capitalization
$355.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progenics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PGNX Stock News Headlines

PGNX_old Historical Data
Investing in Pharmaceutical Stocks
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
I've Got an Options Bandage for a Sick Economy
See More Headlines

PGNX Stock Analysis - Frequently Asked Questions

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings results on Thursday, May, 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.03. The biotechnology company earned $6.25 million during the quarter. Progenics Pharmaceuticals had a negative trailing twelve-month return on equity of 129.46% and a negative net margin of 180.28%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progenics Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Caterpillar (CAT), Exelixis (EXEL), IMAX (IMAX), Bristol Myers Squibb (BMY), Novavax (NVAX) and Citius Pharmaceuticals (CTXR).

Company Calendar

Last Earnings
5/07/2020
Today
7/07/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PGNX
Fax
N/A
Employees
79
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.55 million
Net Margins
-180.28%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$34.99 million
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
7.59

Miscellaneous

Free Float
N/A
Market Cap
$355.05 million
Optionable
Optionable
Beta
1.89
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:PGNX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners